XARELTO
PeakNDAORALTABLET
Approved
Nov 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2070
Data completeness
3/8 — Basic
IRA Negotiated
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XARELTO (rivaroxaban) is an oral anticoagulant small molecule approved in 2011 for prevention and treatment of thromboembolic disorders. It is a Factor Xa inhibitor used across multiple indications including atrial fibrillation, venous thromboembolism, and acute coronary syndrome. Currently in peak lifecycle stage with sustained market demand.
$6.3BPart D
PeakStable
Peak lifecycle status with $6.3B in annual spending indicates mature, stable commercial infrastructure; significant IRA price negotiation in 2026 will require defensive strategy and cost management focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2070)
Computerized Decision Support to Prevent Stroke in Atrial Fibrillation
Started Dec 2026
2,500 enrolled
Atrial FibrillationStroke
Integrating the Guardian Spatial Emanator Within AVENIR II
Started Dec 2026
150,000 enrolled
Malaria
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
Started Sep 2026
300 enrolled
Atrial Fibrillation
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
Started Aug 2026
35 enrolled
Cytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis:A Real-World Prospective Cohort Study.
Started Aug 2026
97 enrolled
Ulcerative Colitis (Disorder)Guselkumab
Worked on XARELTO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.